Arteris Announces Financial Results for the Third Quarter 2021 and Estimated Fourth Quarter and Full Year 2021 Guidance
| |
Three Months Ended | |
Nine Months Ended |
| |
September 30, | |
September 30, |
| |
2021 | |
2020 | |
2021 | |
2020 |
| |
(in thousands) |
| Research and development | $ | 225 | | | $ | 68 | | | $ | 645 | | | $ | 158 | |
| Sales and marketing | 38 | | | 21 | | | 114 | | | 66 | |
| General and administrative | 170 | | | 22 | | | 385 | | | 57 | |
| Total stock-based compensation expense | $ | 433 | | | $ | 111 | | | $ | 1,144 | | | $ | 281 | |
(2) Includes advisory, legal, accounting, valuation, and other professional or consulting fees associated with the Magillem acquisition.
(3) Represents the amortization expenses of our intangible assets attributable to the Magillem acquisition.
(4) Includes amortization of acquired intangible assets as follows:
| |
Three Months Ended | |
Nine Months Ended |
| |
September 30, | |
September 30, |
| |
2021 | |
2020 | |
2021 | |
2020 |
| |
(in thousands) |
| Research and development | $ | 85 | | | $ | — | | | $ | 255 | | | $ | — | |
| Sales and marketing | 34 | | | — | | | 103 | | | — | |
| Total amortization | $ | 119 | | | $ | — | | | $ | 358 | | | $ | — | |
